SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China
Getinge has a strong market share in India within several product segments
Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers
Essex enriches and complements Emmes’ services
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
Proposed combination enhances Pfizer’s position as a leading company in oncology
Twelve hospitals across India will be part of the network which will support the trial in India
Subscribe To Our Newsletter & Stay Updated
